In this study, we identified a significant positive correlation between elevated HSF1 expression and resistance to first-line treatment, along with poorer survival outcomes in DLBCL patients, particularly among those with adverse clinical characteristics, such as advanced-stage disease and high IPI scores. Here, HSF1 is linked to diffuse large B-cell lymphoma.